Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
nasopharyngeal carcinoma |
microarray, qPCR, Western blot, knockdown, ISH etc. |
NPC tissue, cell lines (5-8F, HNE2, HK-1) |
up-regulated |
interaction |
AFAP1-AS1 expression was upregulated in NPC and associated with NPC metastasis and poor prognosis. In vitro experiments demonstrated that AFAP1-AS1 knockdown significantly inhibited the NPC cell migration and invasive capability. AFAP1-AS1 knockdown also increased AFAP1 protein expression. Proteomic and bioinformatics analyses suggested that AFAP1-AS1 affected the expression of several small GTPase family members and molecules in the actin cytokeratin signaling pathway. AFAP1-AS1 promoted cancer cell metastasis via regulation of actin filament integrity. |
26246469 |
Lnc2Cancer
|
Barrett's esophagus |
N/A |
N/A |
N/A |
expression |
Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett's Esophagus and Esophageal Adenocarcinoma. |
23333711 |
LncRNADisease Lnc2Cancer
|
esophageal squamous cell carcinoma |
overexpression, Kaplan-Meier survival analysis |
cisplatin-resistant and parental ESCC cell lines |
up-regulated |
expression |
High expression of AFAP1-AS1 could serve as a potential biomarker to predict tumor response and survival. Determination of this lncRNA expression might be useful for selection ESCC patients for dCRT. |
26756568 |
|
esophageal adenocarcinoma |
qPCR etc. |
EAC tissue, cell lines (OE-33, SK-GT-4, FLO-1, HEEpiC etc.) |
up-regulated |
expression |
Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett's Esophagus and Esophageal Adenocarcinoma. |
23333711 |
LncRNADisease Lnc2Cancer
|
pancreatic ductal adenocarcinoma |
qPCR etc. |
blood, cell lines (Panc1, MIAPaCa-2, Capan2, SW1990 etc.) |
up-regulated |
expression |
Microarray analysis revealed that up-regulation of AFAP1-AS1 expression in PDAC tissues compared with normal adjacent tissues, which was confirmed by RT-qPCR in 69/90 cases (76.7%). Its overexpression was associated with lymph node metastasis, perineural invasion, and poor survival. AFAP1-AS1 is a potential novel prognostic marker to predict the clinical outcome of PDAC patients after surgery and may be a rational target for therapy. |
25925763 |
Lnc2Cancer
|
non-small cell lung cancer |
qPCR etc. |
non-small-cell lung cancer tissue |
up-regulated |
expression |
Results showed that patients with high LncRNA AFAP1-AS1 expression lived shorter than those with low LncRNA AFAP1-AS1 expression (Log rank test, P<0.001). Besides, the prognostic value of LncRNA AFAP1-AS1 as well as the clinical features was assessed by Cox regression analysis. The outcome revealed that LncRNA AFAP1-AS1 was closely related to the prognosis of NSCLC |
26463625 |
Lnc2Cancer
|
hepatocelluar carcinoma |
real-time PCR; MTT assay |
78 HCC tissues |
up-regulated |
N/A |
AFAP1-AS1 was significantly correlated with pathological staging |
26892468 |
|
lung cancer |
RNA-seq, qPCR, Western blot etc. |
cell line (A549 ) |
up-regulated |
interaction |
AFAP1-AS1 was the most significantly upregulated in lung cancer and associated with poor prognosis. AFAP1-AS1 knockdown significantly inhibited the cell invasive and migration capability in lung cancer cells. AFAP1-AS1 knockdown also increased the expression of its antisense protein coding gene, actin filament associated protein 1 (AFAP1), and affected the expression levels of several small GTPase family members and molecules in the actin cytokeratin signaling pathway, which suggested that AFAP1-AS1 promoted cancer cell metastasis via regulation of actin filament integrity. |
26245991 |
Lnc2Cancer
|
|